Skip to main content

Vasculitis Foundation Canada

By Jon Stewart

I TRANSCEND Phase 2

Study is recruiting new or relapsing GPA and MPA ANCA patients to evaluate an investigational drug called Tarperprumig.

The I TRANSCEND Study is a phase 2 trial evaluating the safety, tolerability and effectiveness of an investigational medication in adults who have GPA or MPA anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA Vasculitis).

This study will look at the safety and efficacy of Tarperprumig in adult participants with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.  The study is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of Tarperprumig in adult participants with GPA or MPA ANCA associated vasculitis.

The primary objective of this study is to evaluate the safety and tolerability of Tarperprumig in participants with newly diagnosed or relapsing GPA or MPA ANCA associated vasculitis.

Eligible patient expenses will be reimbursed for the study participant and one caregiver, where permitted. Additional study information can be found in the attached two PDF’s.

For more information on this study please contact the Canadian study sites below.

As of July 15, 2026 the following Canadian I TRANSCEND sites are open for recruitment:

Ontario

Etobicoke
Regional Kidney Metabolic Research Partners 135 Queens Plate Drive Suite 101 Etobicoke, Ontario, M9W 6V1 Investigator: Dr. Bajinder Reen

Coordinator: Andrew Hussain, Contact: 905-638-2000 Ext 2

Toronto
Mount Sinai Hospital 60 Murray Street Room 2-205 Toronto, Ontario, M5T 3L9 Investigator: Dr. Christian Pagnoux

Coordinator: Nazrana Haq, Contact: 416-586-4800 Ext 2210

Hamilton
St. Joseph’s Healthcare Hamilton Martha Wing H326 50 Charlton Avenue East Hamilton, Ontario, L8N 4A6 Investigator: Dr. Michael Walsh

Coordinator: Andrea Mazzetti Vieira, Contact: 905-522-1155 Ext 35368

Québec

Montreal
Hôpital du Sacré-Coeur-de-Montréal 5400 Boul. Gouin Ouest Room E1370 Montreal, Québec H4J 1C5 Investigator: Jean-Paul Makhzoum

Coordinator: Guylaine Marcotte, Contact: 514-338-2222 Ext 3182

Alberta

Edmonton
University of Alberta Hospital 9-114 CSB, 11350 83 Ave NW Edmonton, Alberta, T6G 2B7 Investigator: Jan Wilem Cohen Tervaert

Coordinator Rim Barbar/Abid Alvi, Contact: 780-407-6090

Calgary
Sheldon M Chumir Health Centre University of Calgary 2nd Floor Room No 2318 1213 4th Street SW Calgary, Alberta, T2R 0X7 Investigator: Dr. Louis Girard

Coordinator : Ayo Adeyemo, Contact: 403-955-6385

STUDY FACT SHEET  |  PATIENT BROCHURE